Dermipsor is a clinical-stage drug development company focusing on novel therapies for the dermatology market. Dermipsor’s products offer more effective and safer solutions for patients suffering from psoriasis.

Exceptional Speed: Dermipsor's advanced clinical pipeline was created in record time, and the company expects to bring its first product for plaque psoriasis to the market as early as Q4 2013 - Q1 2014

Exceptional Novelty: Innovative strategies for developing much needed therapies for skin diseases

Exceptional Safety: Dermipsor understands that safety is of paramount importance to dermatology patients and focuses on developing efficacious drugs with a superior safety profile